Thomas Hogan1, H James Williams, Ramin Altaha. 1. Department of Medicine, Robert C. Byrd Health Sciences Center & Mary Babb Randolph Cancer Center, West Virginia University, POB 9162 Morgantown, WV 26506-9162, USA. thogan@hsc.wvu.edu
Abstract
OBJECTIVE: To highlight the molecular findings and clinical response of a patient with rapidly progressing, focally anaplastic, oncocytic thyroid carcinoma (OTC) treated with erlotinib.Case Summary. A 69-year-old woman with recurrent, focally anaplastic OTC was given a therapeutic trial of erlotinib, a small molecule inhibitor of epidermal growth factor receptor (EGFR). Formalin-fixed, paraffin-embedded portions of the tumor were analyzed for EGFR expression, and tumor genomic DNA was amplified by polymerase chain reaction (PCR) and subjected to EGFR mutation analysis.Discussion. An early and dramatic response was achieved with erlotinib. The tumor was focally positive for EGFR by immunostaining and two point mutations were identified, one on exon 18 and one on exon 20 in the tyrosine kinase (TK) domain. CONCLUSION: Erlotinib or other novel protein kinase pathway inhibitors should be evaluated further in patients with aggressive thyroid cancer variants, who may exhibit these and perhaps other tyrosine kinase mutations.
OBJECTIVE: To highlight the molecular findings and clinical response of a patient with rapidly progressing, focally anaplastic, oncocytic thyroid carcinoma (OTC) treated with erlotinib.Case Summary. A 69-year-old woman with recurrent, focally anaplastic OTC was given a therapeutic trial of erlotinib, a small molecule inhibitor of epidermal growth factor receptor (EGFR). Formalin-fixed, paraffin-embedded portions of the tumor were analyzed for EGFR expression, and tumor genomic DNA was amplified by polymerase chain reaction (PCR) and subjected to EGFR mutation analysis.Discussion. An early and dramatic response was achieved with erlotinib. The tumor was focally positive for EGFR by immunostaining and two point mutations were identified, one on exon 18 and one on exon 20 in the tyrosine kinase (TK) domain. CONCLUSION:Erlotinib or other novel protein kinase pathway inhibitors should be evaluated further in patients with aggressive thyroid cancer variants, who may exhibit these and perhaps other tyrosine kinase mutations.
Authors: R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling Journal: J Clin Endocrinol Metab Date: 2013-04-15 Impact factor: 5.958
Authors: P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré Journal: Clin Transl Oncol Date: 2016-04-05 Impact factor: 3.405
Authors: Willem E Corver; Dina Ruano; Karin Weijers; Wietske C E den Hartog; Merlijn P van Nieuwenhuizen; Noel de Miranda; Ronald van Eijk; Anneke Middeldorp; Ekaterina S Jordanova; Jan Oosting; Ellen Kapiteijn; Guido Hovens; Jan Smit; Tom van Wezel; Hans Morreau Journal: PLoS One Date: 2012-06-01 Impact factor: 3.240
Authors: Kelsey L Corrigan; Hannah Williamson; Danielle Elliott Range; Donna Niedzwiecki; David M Brizel; Yvonne M Mowery Journal: J Thyroid Res Date: 2019-05-23